knowledge -WSS

knowledge

author：leisure time 2025-09-29 22:36:51 - browse：666

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： The new shift in health care is toward less care

hotspot

WSS

Addiction doctors spar with methadone clinics over legislation

Do more moles mean more problems? Not so, says new study

David Sabatini, ex

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Just how powerful is the placebo effect?

Dark money group runs ads on China biotech bill

focus

knowledge

entertainment

Continuity nursing helped my family in our darkest PICU moments

Just how powerful is the placebo effect?

Hollywood unions extend contract negotiations for actors

Stigma and the return of syphilis

Novavax promises a turnaround & Lilly roils the obesity market

Will General Catalyst be the first of many hospital takeovers?

Virginia high school admissions case could be legal follow

FDA approves potent Eli Lilly obesity drug, Zepbound

How one medical school became remarkably diverse

Focused ultrasound for uterine fibroids: an uphill battle

leisure time

Childbirth

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

David Sabatini, ex

iTeos Therapeutics debuts first data on TIGIT

iTeos Therapeutics debuts first data on TIGIT

Just how powerful is the placebo effect?

focus

hotspot

hotspot

leisure time